Adult-onset Still's disease (AOSD) is a rare rheumatological condition characterized by an acute systemic involvement. There are no treatment guidelines. Glucocorticoids (GC), methotrexate (MTX), cyclosporin A and biologic agents have been successfully used, often in association. We treated six cases of AOSD with clarithromycin (CM) in combination with low-mild dose of GC and MTX. Four of them were not responsive to high-dose GC added to DMARDs, while two of them were treated with low-mild dose of GC added to CM from the beginning. CM, 500 mg b.i.d., was added to a mild-low dose of GC and to MTX. The dose of the drugs was reduced (and stopped where possible) following clinical and laboratory parameters. ACR criteria were used to assess clinical improvement. At 6 months 5 patients reached ACR 70% and could stop any therapy in 6-18 months; 1 continued chronic therapy with low-dose GC added to CM and MTX to maintain ACR 50%. CM can be a useful drug for the treatment of AOSD, even in patients not responsive to high-dose GC and DMARDs. No definitive conclusion can be drawn based on the present study.

Clarithromicin in adult-onset Still'disease a study of 6 cases / Saviola, G; Benucci, M; Abdi-Ali, L; Baiardi, P; Manfredi, M; Bucci, M; Cirino, G. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 0172-8172. - 30:4(2010), pp. 555-560. [10.1007/s00296-009-1277-9]

Clarithromicin in adult-onset Still'disease a study of 6 cases

Benucci M;Bucci M;Cirino G
2010

Abstract

Adult-onset Still's disease (AOSD) is a rare rheumatological condition characterized by an acute systemic involvement. There are no treatment guidelines. Glucocorticoids (GC), methotrexate (MTX), cyclosporin A and biologic agents have been successfully used, often in association. We treated six cases of AOSD with clarithromycin (CM) in combination with low-mild dose of GC and MTX. Four of them were not responsive to high-dose GC added to DMARDs, while two of them were treated with low-mild dose of GC added to CM from the beginning. CM, 500 mg b.i.d., was added to a mild-low dose of GC and to MTX. The dose of the drugs was reduced (and stopped where possible) following clinical and laboratory parameters. ACR criteria were used to assess clinical improvement. At 6 months 5 patients reached ACR 70% and could stop any therapy in 6-18 months; 1 continued chronic therapy with low-dose GC added to CM and MTX to maintain ACR 50%. CM can be a useful drug for the treatment of AOSD, even in patients not responsive to high-dose GC and DMARDs. No definitive conclusion can be drawn based on the present study.
2010
Clarithromicin in adult-onset Still'disease a study of 6 cases / Saviola, G; Benucci, M; Abdi-Ali, L; Baiardi, P; Manfredi, M; Bucci, M; Cirino, G. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 0172-8172. - 30:4(2010), pp. 555-560. [10.1007/s00296-009-1277-9]
File in questo prodotto:
File Dimensione Formato  
rheumatol int 2010.pdf

accesso aperto

Licenza: Dominio pubblico
Dimensione 252.49 kB
Formato Adobe PDF
252.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/700328
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact